Bristol-Myers Squibb Company (BMY)
| Market Cap | 92.88B |
| Revenue (ttm) | 47.70B |
| Net Income (ttm) | 5.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.49 |
| PE Ratio | 18.36 |
| Forward PE | 7.14 |
| Dividend | $2.48 (5.43%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 10,021,403 |
| Open | 46.10 |
| Previous Close | 46.15 |
| Day's Range | 45.59 - 46.32 |
| 52-Week Range | 42.96 - 63.33 |
| Beta | 0.36 |
| Analysts | Hold |
| Price Target | 57.64 (+26.32%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.64, which is an increase of 26.32% from the latest price.
News
Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends
The Dividend Harvesting Portfolio reached all-time highs, up 34.27% on invested capital and producing $2,573.68 in forward annualized dividend income. Recent additions include NNN REIT, Bristol Myers,...
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers to sell 60% stake in China joint venture
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy
Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as un...
These stock-market experts don't love AI. Here's what they do recommend.
I'll bet you think that investment newsletters' most-recommended stock is Nvidia Corp., the AI-chip-producing giant whose stock has gained more than 30,000% over the past decade.
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum.
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL...
Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky ...
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the G...
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hod...
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy dec...
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
Visa has demonstrated why it remains the market leader in the global payment processor market, thanks to its robust, profitable growth cadence.
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol-Myers Squibb: Not As Cheap As It Might Seem
At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ava...
8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025...
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September...
8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula to identify large-cap value stocks offering strong intrinsic value and stable dividends. Analyst forecasts suggest top-ten GASV 'Dogs' could deliver 1...
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025.
Final Trades: ServiceNow, Bristol Myers and Live Nation
The Investment Committee give you their top stocks to watch for the second half.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...